ClinicalTrials.gg

Program

VXA-G1.1-NN

A development code.

Its studies are mostly in Caliciviridae Infections, led by Vaxart.

Furthest: phase 2, since Apr 19, 20216 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vaxart60 open or runningphase 2since Apr 19, 2021Mar 28, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2019First study: phase 1 study in Caliciviridae InfectionsFirst studyNCT03897309 · 86 enrolled · United States
  2. Apr 19, 2021Phase 2 study in Caliciviridae InfectionsNCT04875676 · 30 enrolled · United States
  3. Jan 18, 2022Phase 1 study in Caliciviridae InfectionsNCT05213728 · 8 enrolled · United States
  4. Jan 25, 2022Phase 2 study in Caliciviridae InfectionsNCT05212168 · 165 enrolled · United States
  5. Apr 17, 2025Phase 1 study in Caliciviridae InfectionsNCT06944717 · 60 enrolled · United States
  6. Nov 19, 2025Phase 1 study in Caliciviridae InfectionsNCT07254728 · 76 enrolled · South Africa

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07254728Caliciviridae Infections · South Africa1CompletedDec 13, 202476
NCT06944717Caliciviridae Infections · United States1CompletedApr 14, 202660
NCT05212168Caliciviridae Infections · United States2CompletedApr 13, 2023165
NCT05213728Caliciviridae Infections · United States1CompletedFeb 1, 20228
NCT04875676Caliciviridae Infections · United States2CompletedOct 30, 202130
NCT03897309Caliciviridae Infections · United States1CompletedJan 15, 202186

How it is read

Names in the registry

  • “VXA-G1.1-NN”, 6 entries

Codes read as this program: VXAG11NN.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.